Glucose-driven histone lactylation promotes immunosuppressive activity in glioblastoma

Linda Liau elected to Taiwan’s Academia Sinica

Linda Liau, chair of neurosurgery at the David Geffen School of Medicine at UCLA, was elected as an Academician of Academia Sinica by the 35th Convocation of Academicians, the preeminent academic institution in Taiwan.

July 12, 2024

Vol.50 No.28

Drugs & Targets

Wistar, Accelerated Biosciences collaborate to develop immune cell therapies

The Wistar Institute is collaborating with Accelerated Biosciences Corp. to create a platform based on human trophoblast stem cells to explore new immunotherapies that use Accelerated Bio’s proprietary technology. This collaboration could generate various types of immune cells from hTSCs, changing the field of allogeneic immunotherapies.

July 12, 2024

Vol.50 No.28

In Brief

Jozef Madzo named director of bioinformatics at Wistar

Jozef Madzo was named director of bioinformatics at the Wistar Institute. He will lead and oversee Wistar’s bioinformatics projects and initiatives across a variety of advanced biomedical research programs.

July 05, 2024

Vol.50 No.27

In Brief

Noam Auslander receives $600K grant to identify connections between gut microbial genes and melanoma immunotherapy

The Wistar Institute’s Noam Auslander, assistant professor in the Molecular and Cellular Oncogenesis Program at the Ellen and Ronald Caplan Cancer Center, was awarded a $600,000 Women Scientists Innovation Award for Cancer Research grant from the V Foundation for Cancer Research.

June 28, 2024

Vol.50 No.26

In Brief

Wistar Institute receives $10M donation

The Wistar Institute received a $10 million donation from an anonymous donor who previously committed $20 million to support Wistar’s new Center for Advanced Therapeutics.

June 21, 2024

Vol.50 No.25

Clinical Roundup

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

A pioneering phase I CAR T-cell therapy trial for the treatment of glioblastoma at City of Hope, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.

June 14, 2024

Vol.50 No.24

Glucose-driven histone lactylation promotes immunosuppressive activity in glioblastoma

YOU MAY BE INTERESTED IN

Linda Liau elected to Taiwan’s Academia Sinica

Wistar, Accelerated Biosciences collaborate to develop immune cell therapies

Jozef Madzo named director of bioinformatics at Wistar

Noam Auslander receives $600K grant to identify connections between gut microbial genes and melanoma immunotherapy

Wistar Institute receives $10M donation

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

Renew today!

Subscriber content

Login